Curasan AG

ots Ad hoc-Service: curasan AG curasan AG increases its sales in 2000 by 38.6 percent

Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement. -----------------------------------------------------

    Kleinostheim(ots Ad hoc-Service) - curasan AG, Kleinostheim, could increase its sales in the business year 2000 by 38.6 percent to 21.3 (15.4) million DM according to the final figures. The figures are slightly above the provisional figure of 21.0 million DM published at the end of December. The most important mainstay of growth was biomaterials / biologicals with a strong increase of 70 percent to 8.5 (5.0) million DM. The field pharmaceuticals also experienced a significant growth of 23.1 percent to 12.8 (10.4) million DM. The gross profit was increased to 14.1 (10.0) million DM. With 40.7 percent this pleasant improvement was even stronger than the increase of the overall performance of 39.4 percent. The EBIT in the group amounted to minus 4.1 (minus 4.1) million DM and is better than the provisional figures of minus 4.6 million DM. In total the profit and loss account of curasan AG doses with an annual deficit in the group of 3.5 (2.0) million DM. The result per share amounted to minus 0.59 (minus 1.09) DM.     For the business year 2001 the board expects an increase in sales of 80 percent to 38 million DM with a break-even result after tax. Curasan AG is currently preparing a product offensive which will significantly increase the pace of growth. In the business year 2001 the market launch of up to 10 new products for different fields of application is planned. The internationalisation within the European Union, Eastern European countries, South America and the Middle East is underway and will even be accelerated. It is planned to increase the portion of sales generated abroad from currently 15 percent (2000) to 45 percent until 2005.

    Further information:

    Helmut Trahmer, curasan AG. Tel 06027-46 86 0; email: Dr. Jürgen Gaulke, Gaulke & Partner Consult, Tel. 0177-679 30 60; email:

    WKN: 549453; Index: Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart

End of message ----------------------------------------------------- Internet:

Original-Content von: Curasan AG, übermittelt durch news aktuell

Weitere Meldungen: Curasan AG

Das könnte Sie auch interessieren: